Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SRNE |
---|---|---|
09:32 ET | 2018 | 0.01 |
09:34 ET | 133 | 0.01 |
09:50 ET | 2000 | 0.0114 |
09:54 ET | 450 | 0.01 |
10:01 ET | 500 | 0.0114 |
10:10 ET | 395 | 0.0114 |
10:15 ET | 108 | 0.01 |
10:33 ET | 400 | 0.0114 |
10:46 ET | 4000 | 0.01 |
11:15 ET | 200 | 0.0114 |
11:20 ET | 500 | 0.01 |
11:40 ET | 1538 | 0.01 |
11:49 ET | 126 | 0.01 |
12:18 ET | 280 | 0.01 |
12:38 ET | 100 | 0.01 |
01:03 ET | 100 | 0.0114 |
01:19 ET | 500 | 0.01 |
01:24 ET | 300 | 0.0114 |
01:46 ET | 250 | 0.0114 |
02:40 ET | 100 | 0.01 |
02:51 ET | 6000 | 0.01 |
03:27 ET | 1000 | 0.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sorrento Therapeutics Inc | 5.5M | 0.0x | --- |
Molecular Templates Inc | 8.6M | -0.3x | --- |
Centogene NV | 10.2M | -0.3x | --- |
Bioqual Inc | 64.8M | 67.8x | -25.28% |
Cidara Therapeutics Inc | 61.3M | -1.7x | --- |
Neptune Wellness Solutions Inc | 95.2K | 0.0x | --- |
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5M |
---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.85 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.